Patent application number | Description | Published |
20090281287 | IL-17 receptor like molecules and uses thereof - The present invention provides for IL-17 receptor like polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, agonists and antagonists (including selective binding agents), and methods for producing IL-17 receptor like polypeptides. Also provided for are methods for treatment, diagnosis, amelioration, or prevention of diseases with IL-17 receptor like polypeptides. | 11-12-2009 |
20090291885 | Conjugated toxin peptide therapeutic agents - Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed. | 11-26-2009 |
20090297520 | Methods of using conjugated toxin peptide therapeutic agents - Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed. | 12-03-2009 |
20090299044 | DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression - Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed. | 12-03-2009 |
20090305399 | DNA encoding OSK1 toxin peptide analogs and vectors and cells for combinant expression - Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed. | 12-10-2009 |
20110045587 | TOXIN PEPTIDE THERAPEUTIC AGENTS - Disclosed is a DNA encoding a composition of matter of the formula | 02-24-2011 |
Patent application number | Description | Published |
20100303820 | METHODS OF TREATMENT USING IL-17E ANTAGONISTS - Novel IL-17 like polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, selective binding agents, and methods for producing IL-17 like polypeptides. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with IL-17 like polypeptides, agonists, or antagonists thereof. | 12-02-2010 |
20110160438 | IL-17 RECEPTOR LIKE MOLECULES AND USES THEREOF - The present invention provides for IL-17 receptor like polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, agonists and antagonists (including selective binding agents), and methods for producing IL-17 receptor like polypeptides. Also provided for are methods for treatment, diagnosis, amelioration, or prevention of diseases with IL-17 receptor like polypeptides. | 06-30-2011 |
20120231006 | ANTI-ORAI1 ANTIGEN BINDING PROTEINS AND USES THEREOF - Disclosed is an isolated antigen binding proteins, such as but not limited to, an antibody or antibody fragment, that specifically bind to SEQ ID NO: 4, the amino acid sequence of extracellular loop 2 (ECL2) of human Orai1. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors and host cells useful in methods of making it, and methods of using it in treating disorders or diseases in patients. | 09-13-2012 |
Patent application number | Description | Published |
20120176155 | RESCALING - A novel method for designing an integrated circuit (“IC”) by resealing an original set of circuits in a design of the IC is disclosed. The original set of circuits to be resealed includes sequential nodes, combinational nodes, and interconnects. Each sequential node is associated with a phase of a clock. The method generates a resealed set of circuits that includes multiple replica sets of the circuits. Each replica set of circuits includes sequential nodes, combinational nodes, and interconnects that are identical to nodes and interconnects in the original set of circuits. Each sequential node is associated with a phase of a clock that is at a fraction of the phase of its corresponding sequential element in the original set. The method connects nodes in each replica set of circuits to a logically equivalent node in another replica set. The method replaces the original set of circuits with the resealed set of circuits. | 07-12-2012 |
20130097575 | Rescaling - A novel method for designing an integrated circuit (“IC”) by rescaling an original set of circuits in a design of the IC is disclosed. The original set of circuits to be rescaled includes sequential nodes, combinational nodes, and interconnects. Each sequential node is associated with a phase of a clock. The method generates a rescaled set of circuits that includes multiple replica sets of the circuits. Each replica set of circuits includes sequential nodes, combinational nodes, and interconnects that are identical to nodes and interconnects in the original set of circuits. Each sequential node is associated with a phase of a clock that is at a fraction of the phase of its corresponding sequential element in the original set. The method connects nodes in each replica set of circuits to a logically equivalent node in another replica set. The method replaces the original set of circuits with the rescaled set of circuits. | 04-18-2013 |
20140210512 | Rescaling - A novel method for designing an integrated circuit (“IC”) by rescaling an original set of circuits in a design of the IC is disclosed. The original set of circuits to be rescaled includes sequential nodes, combinational nodes, and interconnects. Each sequential node is associated with a phase of a clock. The method generates a rescaled set of circuits that includes multiple replica sets of the circuits. Each replica set of circuits includes sequential nodes, combinational nodes, and interconnects that are identical to nodes and interconnects in the original set of circuits. Each sequential node is associated with a phase of a clock that is at a fraction of the phase of its corresponding sequential element in the original set. The method connects nodes in each replica set of circuits to a logically equivalent node in another replica set. The method replaces the original set of circuits with the rescaled set of circuits. | 07-31-2014 |